Strongbridge Drug Patent Portfolio

Strongbridge owns 1 orange book drug protected by 8 US patents Given below is the list of Strongbridge's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11020393 Methods of treating disease with levoketoconazole 02 Mar, 2040
Active
US11278547 Methods of treating disease with levoketoconazole 02 Mar, 2040
Active
US11903940 Methods of treating disease with levoketoconazole 02 Mar, 2040
Active
US10098877 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
Active
US10517868 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
Active
US10835530 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
Active
US11478471 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
Active
US9918984 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
Active


Given below is the list of recent legal activities going on the following drug patents of Strongbridge.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 06 May, 2024 US10835530
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9918984
Recordation of Patent Grant Mailed 20 Feb, 2024 US11903940
Patent eGrant Notification 20 Feb, 2024 US11903940
Patent Issue Date Used in PTA Calculation 20 Feb, 2024 US11903940
Recordation of Patent eGrant 20 Feb, 2024 US11903940
Email Notification 20 Feb, 2024 US11903940
Mail Patent eGrant Notification 20 Feb, 2024 US11903940
Email Notification 01 Feb, 2024 US11903940
Issue Notification Mailed 31 Jan, 2024 US11903940
Application Is Considered Ready for Issue 10 Jan, 2024 US11903940
Dispatch to FDC 10 Jan, 2024 US11903940
Issue Fee Payment Verified 05 Jan, 2024 US11903940
Issue Fee Payment Received 05 Jan, 2024 US11903940
Electronic Review 12 Dec, 2023 US11903940


Strongbridge's Family Patents

Strongbridge drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 31.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Strongbridge Drug List

Given below is the complete list of Strongbridge's drugs and the patents protecting them.


1. Recorlev

Recorlev is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11020393 Methods of treating disease with levoketoconazole 02 Mar, 2040
(15 years from now)
Active
US11278547 Methods of treating disease with levoketoconazole 02 Mar, 2040
(15 years from now)
Active
US11903940 Methods of treating disease with levoketoconazole 02 Mar, 2040
(15 years from now)
Active
US10098877 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
(1 year, 2 months from now)
Active
US10517868 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
(1 year, 2 months from now)
Active
US10835530 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
(1 year, 2 months from now)
Active
US11478471 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
(1 year, 2 months from now)
Active
US9918984 Methods and compositions for treating diabetes, metabolic syndrome and other conditions 10 Jan, 2026
(1 year, 2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recorlev's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List